Table 2.
Pharmacokinetics of LY3298176.
| LY3298176 0.25 mg N = 6 |
LY3298176 0.5 mg N = 12 |
LY3298176 1.0 mg N = 5 |
LY3298176 2.5 mg N = 6 |
LY3298176 5.0 mg N = 5 |
LY3298176 8.0 mg N = 7 |
|
|---|---|---|---|---|---|---|
| SAD cohorts SC Route | ||||||
| Cmax, ng/mL | 26.0 (29) | 57.7 (37) | 108 (14) | 231 (40) | 397 (23) | 874 (19) |
| Tmax, ha | 48 (48,48) | 48 (24, 96) | 24 (8, 48) | 24 (24, 96) | 24 (24, 72) | 48 (24, 72) |
| AUC0-inf, ng.h/mL | 5760 (22) | 12000 (24) | 22600 (14) | 53200 (36) | 90500 (15) | 169000 (8) |
| T1/2, hb | 116 (94.6, 132) | 124 (94.4, 163) | 106 (92.9, 117) | 120 (102, 137) | 123 (99.9, 147) | 111 (99.6, 121) |
| CL/F, L/h | 0.0434 (22) | 0.0416 (24) | 0.0443 (14) | 0.0470 (36) | 0.0553 (15) | 0.0472 (8) |
| Vz/F, L | 7.26 (23) | 7.46 (28) | 6.76 (18) | 8.15 (35) | 9.80 (7) | 7.55 (4) |
Data are Geometric Mean (coefficient of variability CV %), unless otherwise noted. aMedian (minimum, maximum), bGeometric mean (minimum, maximum), Abbreviations: SAD = single ascending dose, Cmax = maximum observed drug concentration, Tmax = time of Cmax, AUC0-inf = area under the concentration time curve from time 0 extrapolate to infinity, CL/F = apparent total body clearance of drug following subcutaneous administration, Vz/F = apparent volume of distribution of drug during terminal phase following subcutaneous administration, N = number of subjects, T1/2 = half-life associated with the terminal rate constant in non-compartmental analysis.